Suppliers / Hetero

Hetero

India 376 employees 8 duplicate records merged Updated 9 July 2026

Hetero is an API and finished-dose manufacturer based in India. It holds 380 active US drug master files and 67 valid CEPs. Its filings concentrate with SAHPRA (ZA), DAV (Vietnam) and ARCSA (EC). Its GMP standing is certified by EMA, US FDA and ANVISA (Brazil), among 12 authorities. Its most recent recorded inspection, by US FDA, closed on 16 May 2025 as VAI.

380
active US DMFs
67
valid CEPs
12
registered plants 3 with an FDA FEI number
1,421
filings across 23 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
3 of 3 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 16 May 2025 VAI US FDA
  • 31 January 2025 NAI US FDA
  • 31 January 2025 NAI US FDA
  • 21 September 2023 VAI US FDA
  • 21 September 2023 VAI US FDA
  • 8 September 2023 VAI US FDA
  • 8 September 2023 VAI US FDA
  • 21 July 2023 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Telangana, Colombia Not on file
Hyderabad, Colombia Not on file
Solan, Colombia Not on file
Baddi, Colombia Not on file
VISAKHAPATNAM, India Not on file
ANDHRA PRADESH, India Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Esomeprazole US FDA 7
Lamivudine EDQM, SFDA (Saudi Arabia), US FDA 7
Lisinopril SFDA (Saudi Arabia), US FDA 7
Omeprazole SFDA (Saudi Arabia), US FDA 7
Escitalopram EDQM, SFDA (Saudi Arabia), US FDA 6
Moxifloxacin SFDA (Saudi Arabia), US FDA 6
Ritonavir SFDA (Saudi Arabia), US FDA 6
Sertraline SFDA (Saudi Arabia), US FDA 6
Aripiprazole EDQM, SFDA (Saudi Arabia), US FDA 5
Atovaquone SFDA (Saudi Arabia), US FDA 5
Show all 30 molecules on file
Donepezil SFDA (Saudi Arabia), US FDA 5
Efavirenz SFDA (Saudi Arabia), US FDA 5
Gabapentin SFDA (Saudi Arabia), US FDA 5
Imatinib Mesilate EDQM 5
Lacosamide SFDA (Saudi Arabia), US FDA 5
Levetiracetam EDQM, SFDA (Saudi Arabia), US FDA 5
Lopinavir SFDA (Saudi Arabia), US FDA 5
Nebivolol SFDA (Saudi Arabia), US FDA 5
Sildenafil SFDA (Saudi Arabia), US FDA 5
Tenofovir Disoproxil SFDA (Saudi Arabia), US FDA 5
Atomoxetine EDQM, SFDA (Saudi Arabia), US FDA 4
Bupropion US FDA 4
Citalopram US FDA 4
Darunavir US FDA 4
Dexlansoprazole US FDA 4
Dolutegravir SFDA (Saudi Arabia), US FDA 4
Emtricitabine SFDA (Saudi Arabia), US FDA 4
Fenofibrate SFDA (Saudi Arabia), US FDA 4
Finasteride EDQM, SFDA (Saudi Arabia), US FDA 4
Letrozole EDQM, SFDA (Saudi Arabia), US FDA 4

Also appears on these molecule pages

Show 108 more molecule pages
Carbidopa API Carboplatin API Cefixime finished dose Cefuroxime finished dose Cefuroxime Axetil finished dose Celecoxib API Citalopram API Clopidogrel API Dapagliflozin finished dose Daptomycin finished dose Desloratadine API Desvenlafaxine API Dexlansoprazole API Diclofenac API Dolutegravir API Duloxetine API Dutasteride API Empagliflozin finished dose Emtricitabine API Eplerenone API Escitalopram API Esomeprazole API Etoricoxib API Ezetimibe API Famotidine API Fenofibrate API Fexofenadine API Finasteride API Furosemide finished dose Gabapentin API Glimepiride API Hydralazine API Hydrochlorothiazide finished dose Indomethacin API Irbesartan API Isotretinoin API Itraconazole finished dose Ketorolac Tromethamine finished dose Lacosamide API Lamivudine API Lamotrigine finished dose Lansoprazole API Lenalidomide API Letrozole API Levetiracetam API Levocetirizine finished dose Levodopa API Levofloxacin API Lidocaine finished dose Linagliptin finished dose Lisinopril API Loratadine finished dose Losartan API Memantine API Mesalamine finished dose Mesalazine finished dose Metoprolol API Miconazole finished dose Mirabegron API Mirtazapine API Montelukast API Moxifloxacin API Mycophenolate Mofetil finished dose Nabumetone API Naproxen API Nebivolol API Olanzapine API Olmesartan API Olmesartan Medoxomil API Omeprazole API Ondansetron finished dose Oxcarbazepine finished dose Paclitaxel API Pantoprazole API Perindopril API Pioglitazone API Pramipexole API Praziquantel finished dose Pregabalin API Propofol finished dose Propranolol finished dose Quetiapine API Ramipril API Ritonavir API Rosuvastatin API Sacubitril finished dose Salbutamol finished dose Semaglutide finished dose Sertraline API Sildenafil API Simvastatin API Sitagliptin finished dose Solifenacin API Sucralfate finished dose Tadalafil finished dose Telmisartan API Tenofovir Disoproxil API Terbinafine API Ticagrelor finished dose Tolvaptan API Topiramate API Valaciclovir API Valacyclovir API Valsartan API Venlafaxine API Vigabatrin API Vildagliptin finished dose Zolmitriptan API

Filings and GMP by regulator

Regulator Filings GMP certificates
SAHPRA (ZA) 407 None
DAV (Vietnam) 208 None
ARCSA (EC) 167 None
INVIMA (CO) 152 3
MINSA (CR) 148 None
TMDA (TZ) 135 None
EMA None 28
US FDA None 9
ANVISA (Brazil) None 8
MFDS (Korea) None 6
EAEU_EEC None 5
NCELS (KZ) None 4
CDSCO (India) None 3
NAFDAC (NG) None 3
UZPHARM (UZ) None 1
GOSPHARMNADZOR (BY) None 1
FDA (GH) None 1

Comparing suppliers?

Choose your molecules and target markets. Hetero comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 6 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 16 May 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates